Personalized cancer immunotherapy for aggressive hypoxic tumors with blockbuster potential. Our Target Mechanism For Treating Hypoxic Tumors: Carbonic Anhydrase IX (CA IX). Our Mission- to fill the gap in treatment of oncology diseases with poor prognosis- to increase survival rate and bring hope to patients who have undergone different types of therapies without success- to deliver novel therapeutics that match the principle of personalized medicine which will help patients to improve the quality of their lives. Crunchbase
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.